[ANOCEF guidelines for the management of brain metastases]

Abstract

The incidence of brain metastases is increasing because of the use of new therapeutic agents, which allow an improvement of overall survival, but with only a poor penetration into the central nervous system brain barriers. The management of brain metastases has changed due to a better knowledge of immunohistochemical data and molecular biological data, the development of new surgical, radiotherapeutic approaches and improvement of systemic treatments. Most of the time, the prognosis is still limited to several months, nevertheless, prolonged survival may be now observed in some sub-groups of patients. The main prognostic factors include the type and subtype of the primitive, age, general status of the patient, number and location of brain metastases, extracerebral disease. The multidisciplinary discussion should take into account all of these parameters. We should notice also that treatments including surgery or radiotherapy may be proposed in a symptomatic goal in advanced phases of the disease underlying the multidisciplinary approach until late in the evolution of the disease. This article reports on the ANOCEF (French neuro-oncology association) guidelines. The management of brain metastases of breast cancers and lung cancers are discussed in the same chapter, while the management of melanoma brain metastases is reported in a separate chapter due to different responses to the brain radiotherapy.

Keywords: Brain metastases; Breast cancer; Cancer du poumon; Cancer du sein; Chemotherapy; Chimiothérapie; Chirurgie; Lung cancer; Melanoma; Mélanome; Métastases cérébrales; Quality of life; Qualité de vie; Radiotherapy; Radiothérapie; Soins de support; Supportive care; Surgery; Targeted therapy; Thérapie ciblée.